- Home
- HBIO vs RANI Comparison
HBIO vs RANI Comparison
Compare HBIO & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBIO
- RANI
- Stock Information
- Founded
- HBIO 1901
- RANI 2012
- Country
- HBIO United States
- RANI United States
- Employees
- HBIO N/A
- RANI 140
- Industry
- HBIO Biotechnology: Laboratory Analytical Instruments
- RANI Medicinal Chemicals and Botanical Products
- Sector
- HBIO Industrials
- RANI Health Care
- Exchange
- HBIO Nasdaq
- RANI Nasdaq
- Market Cap
- HBIO 61.2M
- RANI 55.3M
- IPO Year
- HBIO 2000
- RANI 2021
- Fundamental
- Price
- HBIO $0.99
- RANI $1.66
- Analyst Decision
- HBIO
- RANI Strong Buy
- Analyst Count
- HBIO 0
- RANI 6
- Target Price
- HBIO N/A
- RANI $11.33
- AVG Volume (30 Days)
- HBIO 277.2K
- RANI 2.3M
- Earning Date
- HBIO 03-06-2025
- RANI 03-19-2025
- Dividend Yield
- HBIO N/A
- RANI N/A
- EPS Growth
- HBIO N/A
- RANI N/A
- EPS
- HBIO N/A
- RANI N/A
- Revenue
- HBIO $97,732,000.00
- RANI N/A
- Revenue This Year
- HBIO N/A
- RANI N/A
- Revenue Next Year
- HBIO $4.32
- RANI N/A
- P/E Ratio
- HBIO N/A
- RANI N/A
- Revenue Growth
- HBIO N/A
- RANI N/A
- 52 Week Low
- HBIO $0.94
- RANI $1.24
- 52 Week High
- HBIO $4.70
- RANI $8.75
- Technical
- Relative Strength Index (RSI)
- HBIO 16.00
- RANI 54.80
- Support Level
- HBIO $1.26
- RANI $1.59
- Resistance Level
- HBIO $1.43
- RANI $1.90
- Average True Range (ATR)
- HBIO 0.10
- RANI 0.15
- MACD
- HBIO -0.03
- RANI 0.03
- Stochastic Oscillator
- HBIO 6.05
- RANI 56.36
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.